Compare DexCom, Inc. (DXCM) vs IAC/Interactivecorp (PPLI) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

PPLI trades at $45.30, down 1.29% today, with a bullish technical signal from moving averages but bearish oscillators. The company reported negative earnings in recent quarters, missing estimates, with Q2 2026 results pending. Revenue declined to $2.39B in 2025, though net loss narrowed to $104M. Analyst consensus is bullish with a $55.40 price target, and MGM Resorts is reportedly in acquisition talks.

Outlook: Potential upside exists from acquisition interest and analyst targets, but risks include consecutive earnings misses, revenue decline, and negative cash flow. Investors should weigh M&A prospects against fundamental weaknesses and high debt levels before considering a position.